ClosedResearch announcementOpportunity HT942526NFRPEHDA

DoW Neurofibromatosis Exploration-Hypothesis Development Award

Defense Health Agency Contracting Activity - DHACA · Department of Defense

At a glance

DoW Neurofibromatosis Exploration-Hypothesis Development Award is a closed federal grant opportunity from the Defense Health Agency Contracting Activity - DHACA (Department of Defense). The application deadline was September 22, 2026. Total estimated funding is $1.28M across about 8 awards. The notice is unrestricted by applicant type, subject to any clarifications in the notice. Cost sharing is not required. It is funded under Assistance Listing 12.420 (Military Medical Research and Development).

Summary assembled from the official notice's fields. The official notice governs.

Key facts

Jun 25, 2026Posted
Sep 22, 2026Application deadline
Oct 22, 2026Archivednext date

Posted: Jun 25, 2026
Close date: Sep 22, 2026
Archive date: Oct 22, 2026
Award floor: Not specified
Award ceiling: Not specified
Est. total funding: $1,280,000
Implied average award: $160,000 calculated
Expected awards: 8
Cost sharing: Not required
Funding instrument: Grant
Opportunity category: Discretionary

Typical awards for this program (SAM.gov listing for ALN 12.420, not this notice): This Assistance Listing supports approximately 30 or more programs each year. Overall, awards are expected to range from $100,000 to $20M (consortium) depending on the funding priorities, anticipated number of awards, and project activity/scope within each program for an award period, on average, of 3 to 4 years. The maximum award amount, if any, is specified in each Program Announcement or Broad Agency Announcement.

Implied average = estimated total funding ÷ expected number of awards, calculated by GrantsJunction. Actual awards vary.

Who can apply

Unrestricted (any entity type)

Can your organization apply?

A quick check against the listed applicant types — other requirements in the notice still apply.

Based on the published notice. Review the official notice for complete eligibility requirements.

What it funds

Official synopsis as published by the agency, formatted for readability.

Summary: The fiscal year 2026 (FY26) Neurofibromatosis Research Program (NFRP) Exploration-Hypothesis Development Award (EHDA) supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in neurofibromatosis (NF) research. Studies supported by this award mechanism should lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on strong scientific rationale and study design.

Distinctive Features:

• Innovation: The proposed research project should be innovative. Innovative research may introduce a novel paradigm, challenge existing paradigms, examine existing problems from novel perspectives, or exhibit other highly creative qualities.

• Preliminary Data: Preliminary and/or published data is encouraged but not required.

Full announcement & documents

The full announcement has the complete rules — page limits, required attachments, evaluation criteria and any letter-of-intent dates. Files download directly from Grants.gov.

FY26 NFRP EHDA Program AnnouncementFull Announcement · HT042526NFRPEHDA_GG.pdfPDF · 474 KB

Assistance Listing

What is an ALN?

12.420Military Medical Research and DevelopmentProgram →

Reported obligations under ALN 12.420

Historical data · not a prediction

FY24

$1.48B

FY25

$1.2B

FY26

— est.

Source: SAM.gov Assistance Listing 12.420. Program-wide totals, not awards from this specific opportunity.

Who was funded under ALN 12.420

Historical data · not a prediction

Since October 1, 2023, 6,147 grant awards had funding actions under Military Medical Research and Development, with 2,218 sub-awards passed on to other organizations. These are program-wide awards, not awards from this specific notice.

THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.$139M
THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER$118M
REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE$81.8M
THE JOHNS HOPKINS UNIVERSITY$72.4M
UNIVERSITY OF CALIFORNIA, LOS ANGELES$62.2M

Recipients, states, recent awards and sub-awards →Source: USAspending.gov.

Agency contact (as published)

Ebony S Simmons Grantor
help@eBRAP.org
301-619-2105

Quick answers

Who is eligible to apply for “DoW Neurofibromatosis Exploration-Hypothesis Development Award”?

The notice lists eligibility as unrestricted — open to any type of entity — subject to clarifications in the notice's additional eligibility information.

How much funding is available through “DoW Neurofibromatosis Exploration-Hypothesis Development Award”?

Per the notice, total estimated program funding is $1,280,000 and the agency expects to make about 8 awards.

How do I apply for “DoW Neurofibromatosis Exploration-Hypothesis Development Award”?

Applications are submitted through the official source, not through GrantsJunction. Open the official notice on Grants.gov (opportunity HT942526NFRPEHDA), and review the full announcement and application package. Organizations applying through Grants.gov generally need an active SAM.gov registration and a Grants.gov account, which can take several weeks to set up.

Matched on shared Assistance Listings, agency, categories and eligible applicant types.

Closes in 4 daysResearchALN 12.420